BIOMAT Database Logo BIOMAT Database Logo

Topical retinaldehyde on human skin: biologic effects and tolerance. 1994

J H Saurat, and L Didierjean, and E Masgrau, and P A Piletta, and S Jaconi, and D Chatellard-Gruaz, and D Gumowski, and I Masouyé, and D Salomon, and G Siegenthaler
Department of Dermatology, University Hospital, Geneva, Switzerland.

The present study was designed to explore if *etinaldehyde, a natural metabolite of vitamin A, has any biologic activity and is tolerated by human skin. Biologic activity was shown by the induction of cellular retinoic acid-binding protein type 2 (CRABP 2) mRNA and protein; the rank order for CRABP-2 increase was retinoic acid > retinaldehyde > 9 cis retinoic acid > retinol > beta carotene. In volunteers treated 1-3 months with 0.5, 0.1, and 0.05% retinaldehyde, there was a dose-dependent and significant increase in epidermal thickness, keratin 14 immunoreactivity, and Ki67-positive cells. The area of distribution of involucrin, transglutaminase, and filaggrin immunoreactivity was also increased in a dose-dependent manner, and keratin 4 immunoreactivity was induced in the upper epidermis. In pilot clinical tolerance studies, 229 patients received topical retinaldehyde at different concentrations; the 1% preparation was tolerated by up to 70% of the treated subjects; tolerance of the 0.5% preparation was slightly better, whereas both 0.1 and 0.05% preparations applied on facial skin were well tolerated and allowed prolonged use (up to 3 years) in patients with inflammatory dermatoses. These findings indicate that topical retinaldehyde has biologic activity and is well tolerated on human skin.

UI MeSH Term Description Entries
D007107 Immune System The body's defense mechanism against foreign organisms or substances and deviant native cells. It includes the humoral immune response and the cell-mediated response and consists of a complex of interrelated cellular, molecular, and genetic components. Immune Systems,System, Immune,Systems, Immune
D007381 Intermediate Filament Proteins Filaments 7-11 nm in diameter found in the cytoplasm of all cells. Many specific proteins belong to this group, e.g., desmin, vimentin, prekeratin, decamin, skeletin, neurofilin, neurofilament protein, and glial fibrillary acid protein. Fibroblast Intermediate Filament Proteins,Filament Proteins, Intermediate,Proteins, Intermediate Filament
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D011498 Protein Precursors Precursors, Protein
D011503 Transglutaminases Transglutaminases catalyze cross-linking of proteins at a GLUTAMINE in one chain with LYSINE in another chain. They include keratinocyte transglutaminase (TGM1 or TGK), tissue transglutaminase (TGM2 or TGC), plasma transglutaminase involved with coagulation (FACTOR XIII and FACTOR XIIIa), hair follicle transglutaminase, and prostate transglutaminase. Although structures differ, they share an active site (YGQCW) and strict CALCIUM dependence. Glutaminyl-Peptide Gamma-Glutamyltransferases,Protein-Glutamine gamma-Glutamyltransferases,Transglutaminase,Gamma-Glutamyltransferases, Glutaminyl-Peptide,Glutaminyl Peptide Gamma Glutamyltransferases,Protein Glutamine gamma Glutamyltransferases,gamma-Glutamyltransferases, Protein-Glutamine
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D004817 Epidermis The external, nonvascular layer of the skin. It is made up, from within outward, of five layers of EPITHELIUM: (1) basal layer (stratum basale epidermidis); (2) spinous layer (stratum spinosum epidermidis); (3) granular layer (stratum granulosum epidermidis); (4) clear layer (stratum lucidum epidermidis); and (5) horny layer (stratum corneum epidermidis).
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000091344 Filaggrin Proteins S100 proteins that aggregate KERATINS. Filaggrin precursor proteins are localized in keratohyalin granules and processed into individual functional filaggrin molecules during terminal epidermis differentiation. Mutations in fillagrins are associated with ICHTHYOSIS VULGARIS. Filaggrin,Filaggrin Protein,Profilaggrin,Stratum Corneum Basic Protein,Stratum Corneum Basic Protein Precursor,Protein, Filaggrin,Proteins, Filaggrin
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations

Related Publications

J H Saurat, and L Didierjean, and E Masgrau, and P A Piletta, and S Jaconi, and D Chatellard-Gruaz, and D Gumowski, and I Masouyé, and D Salomon, and G Siegenthaler
Plasma retinoids after topical use of retinaldehyde on human skin.
January 1996, Skin pharmacology : the official journal of the Skin Pharmacology Society,
J H Saurat, and L Didierjean, and E Masgrau, and P A Piletta, and S Jaconi, and D Chatellard-Gruaz, and D Gumowski, and I Masouyé, and D Salomon, and G Siegenthaler
Tolerance of topical retinaldehyde in humans.
January 1999, Dermatology (Basel, Switzerland),
J H Saurat, and L Didierjean, and E Masgrau, and P A Piletta, and S Jaconi, and D Chatellard-Gruaz, and D Gumowski, and I Masouyé, and D Salomon, and G Siegenthaler
Clinical use of topical retinaldehyde on photoaged skin.
January 1999, Dermatology (Basel, Switzerland),
J H Saurat, and L Didierjean, and E Masgrau, and P A Piletta, and S Jaconi, and D Chatellard-Gruaz, and D Gumowski, and I Masouyé, and D Salomon, and G Siegenthaler
The effects of topical corticosteroids on human skin.
January 1991, Annals of the Academy of Medicine, Singapore,
J H Saurat, and L Didierjean, and E Masgrau, and P A Piletta, and S Jaconi, and D Chatellard-Gruaz, and D Gumowski, and I Masouyé, and D Salomon, and G Siegenthaler
Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin.
January 1997, Journal of the American Academy of Dermatology,
J H Saurat, and L Didierjean, and E Masgrau, and P A Piletta, and S Jaconi, and D Chatellard-Gruaz, and D Gumowski, and I Masouyé, and D Salomon, and G Siegenthaler
Efficacy of topical 0.05% retinaldehyde in skin aging by ultrasound and rheological techniques.
January 1999, Dermatology (Basel, Switzerland),
J H Saurat, and L Didierjean, and E Masgrau, and P A Piletta, and S Jaconi, and D Chatellard-Gruaz, and D Gumowski, and I Masouyé, and D Salomon, and G Siegenthaler
Topical retinaldehyde treatment in oral lichen planus and leukoplakia.
January 2002, International journal of tissue reactions,
J H Saurat, and L Didierjean, and E Masgrau, and P A Piletta, and S Jaconi, and D Chatellard-Gruaz, and D Gumowski, and I Masouyé, and D Salomon, and G Siegenthaler
Topical drug vehicle effects on skin and inflammation.
June 1997, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
J H Saurat, and L Didierjean, and E Masgrau, and P A Piletta, and S Jaconi, and D Chatellard-Gruaz, and D Gumowski, and I Masouyé, and D Salomon, and G Siegenthaler
Biologic effects of solar radiation on man. Effects on the skin.
January 1974, Progress in biometeorology. Division A: Progress in human biometeorology,
J H Saurat, and L Didierjean, and E Masgrau, and P A Piletta, and S Jaconi, and D Chatellard-Gruaz, and D Gumowski, and I Masouyé, and D Salomon, and G Siegenthaler
Effects of topical negative pressure therapy on perfusion and microcirculation of human skin.
January 2019, Clinical hemorheology and microcirculation,
Copied contents to your clipboard!